GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Price-to-Owner-Earnings

Clearmind Medicine (Clearmind Medicine) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Price-to-Owner-Earnings?

As of today (2024-06-19), Clearmind Medicine's share price is $1.23. Clearmind Medicine does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Clearmind Medicine's Price-to-Owner-Earnings or its related term are showing as below:


CMND's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.725
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), Clearmind Medicine's share price is $1.23. Clearmind Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-19.40. Therefore, Clearmind Medicine's PE Ratio for today is At Loss.

As of today (2024-06-19), Clearmind Medicine's share price is $1.23. Clearmind Medicine's EPS without NRI for the trailing twelve months (TTM) ended in was $-17.92. Therefore, Clearmind Medicine's PE Ratio without NRI for today is At Loss.


Clearmind Medicine Price-to-Owner-Earnings Historical Data

The historical data trend for Clearmind Medicine's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Price-to-Owner-Earnings Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Clearmind Medicine Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clearmind Medicine's Price-to-Owner-Earnings

For the Biotechnology subindustry, Clearmind Medicine's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Price-to-Owner-Earnings falls into.



Clearmind Medicine Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Clearmind Medicine's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.23/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clearmind Medicine  (NAS:CMND) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Clearmind Medicine Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine (Clearmind Medicine) Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.